b'Our latest clinical results What were the results?The results showed similar bioavailability of nanoformed piroxicam compared to both reference products, confirm value proposition with no statistically significant difference in maximum plasma concentrations (C max ). Meanwhile, nanoformed piroxicam demonstrated a time of maximum plasma concentration (T= 1.75 h, ranging maxfrom 0.75 h to 4.00 h) earlier relative to both reference products: Felden (T= 2.75 h, ranging from to the pharma industry 0.75 h to 12.00 h) and Brexidol (T max max= 2.25 h, ranging from 0.5 h to 8.00 h). The slightly faster absorption observed for the nanoformed piroxicam tablets compared to Brexidolshows that nanoforming can be used as an alternative or improvement to complex formulation What did we study? approaches, such as those using -cyclodextrin, with the potential for having improved performance In partnership with Quotient Sciences, we completed a human trial of an immediate-release (IR) without the need for additional excipients.tablet formulation of piroxicamthe worlds first human trial of a nanoformed drug candidate. The 20mg nanoformed piroxicam tablets were tested against reference products Felden 20 mg What are the conclusions?tablets (Pfizer) and Brexidol 20 mg tablets (Chiesi) in healthy subjects in the fasted state. Brexidol The results support our value proposition that nanoparticles can enable a faster dissolution rate,is a -cyclodextrin coupled formulation designed for fast absorption, so rapid absorption for this more rapid absorption, and improved drug delivery performance. By improving absorption and reference product was expected in vivo.increasing drug load while also enabling simpler formulations, novel therapies can potentiallybe developed using our CESS technology that ultimately maximize patient benefit. 14 15'